drugset / Trial / NCT00121849
Safety Study to Evaluate the Leish-111f + MPL-SE Vaccine in the Prevention of Cutaneous Leishmaniasis in Healthy Subjects Previously Exposed to the Leishmania Parasite
Phase 1
Completed
12 enrolled
Access to Advanced Health Institute (AAHI)
Bill and Melinda Gates Foundation · collab
Non-randomizedSingle-groupOpen-labelPrevention
Summary
This study will evaluate the safety of the Leish-111f + MPL-SE vaccine in adult subjects with a previous exposure to the Leishmania parasite (but without current or past history of leishmaniasis).
Timeline
- Start
- 2005-08
- Primary completion
- —
- Completion
- 2006-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leish-111f | Protein / enzyme biologic | 10 ug | — |
| Background | MPL-SE | Other / unclassified | 25 ug | — |